Evidence map›Paper›PMID 34172001›Full record

ArticleBMC neurology2021

Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia.

Fabian Hofmeister, Lisa Baber, Uta Ferrari, Stefan Hintze, Stefanie Jarmusch, Sabine Krause, Peter Meinke, Stefan Mehaffey, Carl Neuerburg, Fabiana Tangenelli and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. ReducedAntioxidants (Basel, Switzerland) · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Fabian HofmeisterDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany.
Lisa BaberDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany.
Uta FerrariDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany.
Stefan HintzeDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Stefanie JarmuschDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany.
Sabine KrauseDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Peter MeinkeDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Stefan MehaffeyDepartment of General-, Trauma- and Reconstructive Surgery, University Hospital, LMU Munich, Munich, Germany.
Carl NeuerburgDepartment of General-, Trauma- and Reconstructive Surgery, University Hospital, LMU Munich, Munich, Germany.
Fabiana TangenelliDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany.
Benedikt SchoserDepartment of Neurology, Friedrich-Baur-Institute, University Hospital, LMU Munich, Munich, Germany.
Michael DreyDepartment of Medicine IV, Geriatrics, University Hospital, LMU Munich, Munich, Germany. Michael.Drey@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-6709-9672
LMU Klinikum · DEFriedrich Baur Stiftung · DE

Funding

H2020 Marie Skłodowska-Curie Actions 721577
6 · The paper itself

Abstract

backgroundSarcopenia is the age-related loss of muscle mass and strength. Undiagnosed late-onset neuromuscular disorders need to be considered in the differential diagnosis of sarcopenia.

aimBased on emblematic case reports and current neuromuscular diagnostic guidelines for three common late-onset neuromuscular disorders, a differential diagnostic approach for geriatric patients presenting with a sarcopenic phenotype is given.

methodsPatients over 65 years of age with sarcopenia, amyotrophic lateral sclerosis, inclusion body myositis and myotonic dystrophy type 2 were recruited. All patients were assessed for sarcopenia based on the revised European consensus definition. Patients with neuromuscular diseases were diagnosed according to the revised El Escorial criteria and the European neuromuscular centre criteria. Phenotypes and diagnostic criteria for all patients were summarized including their specific histopathological findings.

resultsAll patients with neuromuscular diseases were positively screened for sarcopenia and classified as severe sarcopenic by means of assessment. The clinical phenotype, the evolution pattern of weakness and muscle atrophy combined with laboratory finding including electromyography could unquestionably distinguish the diseases. DISCUSSION: Neuromuscular disorders can manifest beyond the age of 65 years and misdiagnosed as sarcopenia. The most common diseases are inclusion body myositis, amyotrophic lateral sclerosis and myotonic dystrophy type 2. A diagnostic work-up for neuromuscular diseases ensures their correct diagnosis by clinical-, electrophysiological, histopathological, and genetic work-up.

conclusionsIn geriatric patients with a focal or asymmetrical muscular weakness and atrophy, sarcopenia assessment should be extended with patient's history of disease course. Furthermore, concomitant diseases, analysis of serum creatine kinase, electrophysiological examination, and in selected patients muscle biopsy and gene analysis is needed to rule out a late-onset neuromuscular disorder.

Indexed as

AgedAged, 80 and overAmyotrophic Lateral SclerosisDiagnosis, DifferentialElectromyographyHumansMyotonic DystrophyNeuromuscular DiseasesSarcopeniaAmyotrophic lateral sclerosisInclusion body myositisMyotonic dystrophy type 2Neuromuscular diseaseSarcopenia

Identifiers

PMID34172001
PMCPMC8229316
OpenAlexW3175919684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.